^
    3d
    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=990, Not yet recruiting, Zenas BioPharma (USA), LLC | N=330 --> 990
    Enrollment change
    |
    Inokai (orelabrutinib)
    4d
    RITZ: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (clinicaltrials.gov)
    P3, N=122, Active, not recruiting, International Extranodal Lymphoma Study Group (IELSG) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)
    4d
    LP-168-CN201: A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    rocbrutinib (LP-168)
    4d
    ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL (clinicaltrials.gov)
    P3, N=306, Not yet recruiting, Newave Pharmaceutical Inc
    New P3 trial
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    |
    TP53 mutation
    |
    Jaypirca (pirtobrutinib) • rocbrutinib (LP-168)
    5d
    Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas. (PubMed, Blood Neoplasia)
    Altogether, these findings suggest administering ibrutinib before leukapheresis may modify T-cell characteristics in the collected material, thereby improving final CAR T-cell product quality and clinical outcomes for patients with R/R LBLC treated with tisagenlecleucel. This trial was registered at www.clinicaltrials.gov as #NCT03876028.
    Clinical • Journal
    |
    IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    Imbruvica (ibrutinib) • Kymriah (tisagenlecleucel-T)
    5d
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    5d
    Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Canadian Cancer Trials Group
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    6d
    A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
    P2, N=127, Active, not recruiting, Biogen | Recruiting --> Active, not recruiting | N=275 --> 127
    Enrollment closed • Enrollment change
    7d
    Fat Mass and Obesity-Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B-Cell Lymphoma by Suppressing N6-Methyladenosine Methylation of Myc. (PubMed, Kaohsiung J Med Sci)
    Overall, FTO promotes DLBCL progression and ibrutinib resistance by demethylating Myc mRNA and stabilizing its expression. These findings highlight the FTO-m6A-Myc axis as a potential therapeutic target for overcoming drug resistance in DLBCL.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
    |
    Imbruvica (ibrutinib)
    10d
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Dec 2025 --> Apr 2026
    Trial initiation date
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)
    11d
    15-H-0016: Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL (clinicaltrials.gov)
    P2, N=48, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Calquence (acalabrutinib)
    12d
    ACE-CL-208: A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Acerta Pharma BV | Trial completion date: Sep 2026 --> Jun 2026
    Trial completion date
    |
    Imbruvica (ibrutinib) • Calquence (acalabrutinib)